BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Accenture
US Army
Dow
AstraZeneca
Federal Trade Commission
McKesson
Covington
QuintilesIMS

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,765,117

« Back to Dashboard

Summary for Patent: 6,765,117
Title: Process for stereoselective synthesis of prostacyclin derivatives
Abstract:An improved method is described for making 9-deoxy-PGF.sub.1 -type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds. The invention also relates to novel intermediates prepared during the synthesis of the 9-deoxy-PGF.sub.1 -type compounds.
Inventor(s): Moriarty; Robert M. (Oak Park, IL), Penmasta; Raju (Bolingbrook, IL), Guo; Liang (Chicago, IL), Rao; Munagala S. (Westmont, IL), Staszewski; James P. (Naperville, IL)
Assignee: United Therapeutic Corporation (Washington, DC)
Application Number:10/184,907
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 6,765,117

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-001 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-002 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-003 May 21, 2002 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap REMODULIN treprostinil INJECTABLE;IV (INFUSION), SUBCUTANEOUS 021272-004 May 21, 2002 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap TYVASO treprostinil SOLUTION;INHALATION 022387-001 Jul 30, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-001 Dec 20, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-002 Dec 20, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-003 Dec 20, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-004 Dec 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-005 Oct 7, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,765,117

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,441,245 Process for stereoselective synthesis of prostacyclin derivatives ➤ Subscribe
6,528,688 Prostacyclin derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,765,117

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 245628 ➤ Subscribe
Canada 2307163 ➤ Subscribe
Canada 2847985 ➤ Subscribe
China 1264819 ➤ Subscribe
China 1283184 ➤ Subscribe
Germany 69816642 ➤ Subscribe
Denmark 1025083 ➤ Subscribe
European Patent Office 1025083 ➤ Subscribe
Spain 2198760 ➤ Subscribe
Japan 2004500303 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
McKinsey
Farmers Insurance
Novartis
Accenture
Healthtrust
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot